SEOM Clinical guidelines for the treatment of metastatic prostate cancer

Por Cassinello, J., Climent, M. A., González del Alba, A., Mellado, B., Virizuela, J. A.
Publicado no Clin Transl Oncol (2014)

SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)

Por Cassinello, J., Arranz, J. Á., Piulats, J. M., Sánchez, A., Pérez-Valderrama, B., Mellado, B., Climent, M. Á., Olmos, D., Carles, J., Lázaro, M.
Publicado no Clin Transl Oncol (2017)

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

Por del Muro, X García, Marcuello, E, Gumá, J, Paz-Ares, L, Climent, M A, Carles, J, Parra, M Sánchez, Tisaire, J L, Maroto, P, Germá, J R
Publicado em 2002

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to...

Por Fizazi, K, Ulys, A, Sengeløv, L, Moe, M, Ladoire, S, Thiery-Vuillemin, A, Flechon, A, Guida, A, Bellmunt, J, Climent, M A, Chowdhury, S, Dumez, H, Matouskova, M, Penel, N, Liutkauskiene, S, Stachurski, L, Sternberg, C N, Baton, F, Germann, N, Daugaard, G
Publicado no Ann Oncol (2017)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Por Fradet, Y, Bellmunt, J, Vaughn, D J, Lee, J L, Fong, L, Vogelzang, N J, Climent, M A, Petrylak, D P, Choueiri, T K, Necchi, A, Gerritsen, W, Gurney, H, Quinn, D I, Culine, S, Sternberg, C N, Nam, K, Frenkl, T L, Perini, R F, de Wit, R, Bajorin, D F
Publicado no Ann Oncol (2019)

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Por Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Mai, Y., Poehlein, C.H., Perini, R.F., Bajorin, D.F.
Publicado no N Engl J Med (2017)

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative b...

Por Conteduca, V., Wetterskog, D., Sharabiani, M. T. A., Grande, E., Fernandez-Perez, M. P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez-Estevez, S., González del Alba, A., Mellado, B., Fernandez-Calvo, O., Méndez-Vidal, M. J., Climent, M. A., Duran, I., Gallardo, E., Rodriguez, A., Santander, C., Sáez, M. I., Puente, J., Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., De Giorgi, U., Gonzalez-Billalabeitia, E., Attard, G.
Publicado no Ann Oncol (2017)

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Por Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Láng, I., Gómez, H. L., Tondini, C., Ciruelos, E., Burstein, H. J., Bonnefoi, H. R., Bellet, M., Martino, S., Geyer, C. E., Goetz, M. P., Stearns, V., Pinotti, G., Puglisi, F., Spazzapan, S., Climent, M. A, Pavesi, L., Ruhstaller, T., Davidson, N. E., Coleman, R., Debled, M., Buchholz, S., Ingle, J. N., Winer, E. P., Maibach, R., Rabaglio‑Poretti, M., Ruepp, B., Di Leo, A., Coates, A. S., Gelber, R. D., Goldhirsch, A., Regan, M.M.
Publicado no N Engl J Med (2018)